Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02152319 · ClinicalTrials.gov registry record · NA

Automated Telehealth Diagnostics for Remote Parkinson Monitoring

A NA study of Parkinson's Disease, sponsored by Great Lakes NeuroTechnologies.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT02152319: Completed NA study of Parkinson's Disease, sponsored by Great Lakes NeuroTechnologies.

NCT02152319 is a NA study of Parkinson's Disease that has completed, run by Great Lakes NeuroTechnologies. The registered enrollment target is 21 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02152319, a NA study of Parkinson's Disease, has completed, sponsored by Great Lakes NeuroTechnologies.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The objective is to clinically assess the Kinesia HomeView system for automated and remote monitoring of Parkinson's disease (PD) motor symptoms.

Primary Outcome

Percent of subjects who successfully completed the requested home-based Kinesia HomeView (KHV) automated motor assessments.

Conditions Studied

Interventions

  • PROCEDURE Standard care
  • DEVICE KHV reporting

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2014-05
Est. Completion 2016-02
Phase NA
Great Lakes NeuroTechnologies

17 total trials

What the finished NCT02152319 record still lists

NCT02152319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard care is the first listed.

NCT02152319 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02152319 about?

NCT02152319 is a clinical study titled "Automated Telehealth Diagnostics for Remote Parkinson Monitoring". The objective is to clinically assess the Kinesia HomeView system for automated and remote monitoring of Parkinson's disease (PD) motor symptoms.

What is the current status of trial NCT02152319?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-05. Estimated completion is 2016-02.

What conditions does trial NCT02152319 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02152319?

The interventions under investigation include: Standard care (PROCEDURE), KHV reporting (DEVICE).

Who is sponsoring clinical trial NCT02152319?

This trial is sponsored by Great Lakes NeuroTechnologies, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02152319 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02152319's enrollment target sits among peer trials

21 127th of 158 higher than 31 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02152319, the US trial registry maintained by the National Library of Medicine. NCT02152319 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.